Discover
ELVN
Enliven Therapeutics, Inc.
58.78
2 x 57.35
3 x 59.00
bid
ask
-
0.64
1.08%
2 @ 04:00 PM
58.78 +0.00 (0.00%)
| Ytd | 281.69% | |
| 1y | 224.57% |
57.39
day range
59.27
14.79
52 week range
62.32
| Open | 59.25 | Prev Close | 59.42 | Low | 57.39 | High | 59.27 | Mkt Cap | 4.20B |
| Vol | 0.00 | Avg Vol | 1.42M | EPS | -1.67 | P/E | -35.20 | Forward P/E | -25.89 |
| Beta | 0.24 | Short Ratio | 4.54 | Inst. Own | 88.49% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-13 | 50-d Avg | 48.71 | 200-d Avg | 33.96 | 1yr Est | 72.22 |
| Income Statement | |||
| Operating Expenses | 37.21M | ||
| Research and Development Expense | 29.00M | ||
| Selling, General and Administrative Expense | 8.21M | ||
| Operating Income | -37.21M | ||
| Net Income | -32.48M | ||
| Net Income Common Stock | -32.48M | ||
| Net Income Common Stock (USD) | -32.48M | ||
| Consolidated Income | -32.48M | ||
| Earnings per Basic Share | -0.49 | ||
| Earnings per Basic Share (USD) | -0.49 | ||
| Earnings per Diluted Share | -0.49 | ||
| Earning Before Interest & Taxes (EBIT) | -32.48M | ||
| Earning Before Interest & Taxes (USD) | -32.48M | ||
| Weighted Average Shares | 66.17M | ||
| Weighted Average Shares Diluted | 66.17M | ||
| Balance Sheet | |||
| Cash and Equivalents | 135.51M | ||
| Cash and Equivalents (USD) | 135.51M | ||
| Investments | 759.65M | ||
| Investments Current | 759.65M | ||
| Current Assets | 907.34M | ||
| Property, Plant & Equipment Net | 1.64M | ||
| Total Assets | 910.22M | ||
| Current Liabilities | 14.16M | ||
| Total Liabilities | 15.07M | ||
| Accumulated Retained Earnings (Deficit) | -403.28M | ||
| Accumulated Other Comprehensive Income | -1.90M | ||
| Shareholders Equity | 895.15M | ||
| Shareholders Equity (USD) | 895.15M | ||
| Assets Non-Current | 2.88M | ||
| Liabilities Non-Current | 913.00K | ||
| Trade and Non-Trade Payables | 371.00K | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 133.00K | ||
| Net Cash Flow from Financing | 463.42M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 3.32M | ||
| Capital Expenditure | -99.00K | ||
| Issuance (Purchase) of Equity Shares | 463.42M | ||
| Net Cash Flow from Investing | -441.57M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | -441.47M | ||
| Net Cash Flow from Operations | -18.53M | ||
| Share Based Compensation | 13.92M | ||